# SeaStar Medical Holding Corp: overview

ICU · Nasdaq · CIK 1831868 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/icu.md) · [Financials](/companies/icu/financials.md) · [Filings](/companies/icu/filings.md) · [Insiders](/companies/icu/insiders.md)

Latest reported revenue: [$615.0k](/filings/0001437749-26-027353.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-027353).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [68.0](/filings/0001437749-25-034884.md) | [67.0 d](/filings/0001437749-26-009797.md) | [293](/filings/0001437749-26-016764.md) | [338](/filings/0001437749-26-027353.md) | [183](/filings/0001437749-25-034884.md) | [420 d](/filings/0001437749-26-009797.md) | [495](/filings/0001437749-26-016764.md) | [615](/filings/0001437749-26-027353.md) |
| Gross margin | % | [100.0%](/filings/0001437749-25-034884.md) | [100.0% d](/filings/0001437749-26-009797.md) | [100.0%](/filings/0001437749-26-016764.md) | [92.0%](/filings/0001437749-26-027353.md) | [92.3%](/filings/0001437749-25-034884.md) | [97.1% d](/filings/0001437749-26-009797.md) | [90.7%](/filings/0001437749-26-016764.md) | [91.2%](/filings/0001437749-26-027353.md) |
| Operating margin | % | [(6552.9%)](/filings/0001437749-25-034884.md) | [(7114.9%) d](/filings/0001437749-26-009797.md) | [(1304.4%)](/filings/0001437749-26-016764.md) | [(519.5%)](/filings/0001437749-26-027353.md) | [(1955.7%)](/filings/0001437749-25-034884.md) | [(718.1%) d](/filings/0001437749-26-009797.md) | [(727.9%)](/filings/0001437749-26-016764.md) | [(616.4%)](/filings/0001437749-26-027353.md) |
| Net margin | % | [(6585.3%)](/filings/0001437749-25-034884.md) | [(6595.5%) d](/filings/0001437749-26-009797.md) | [(1287.4%)](/filings/0001437749-26-027353.md) | [(592.3%)](/filings/0001437749-26-027353.md) | [(1897.3%)](/filings/0001437749-25-034884.md) | [(691.4%) d](/filings/0001437749-26-009797.md) | [(711.3%)](/filings/0001437749-26-027353.md) | [(606.5%)](/filings/0001437749-26-027353.md) |
| Diluted EPS | $ per share | [(1.10)](/filings/0000950170-24-126498.md) | not reported | [(0.44)](/filings/0000950170-25-071583.md) | [(0.18)](/filings/0001831868-25-000007.md) | not reported | not reported | not reported | not reported |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | [0.0](/filings/0000950170-25-046200.md) | [135](/filings/0001437749-26-009797.md) | [1,234](/filings/0001437749-26-009797.md) |
| Gross margin | % | not reported | not reported | not reported | [100.0%](/filings/0001437749-26-009797.md) | [95.7%](/filings/0001437749-26-009797.md) |
| Operating margin | % | not reported | not reported | not reported | [(13216.3%)](/filings/0001437749-26-009797.md) | [(986.6%)](/filings/0001437749-26-009797.md) |
| Net margin | % | not reported | not reported | not reported | [(18392.6%)](/filings/0001437749-26-009797.md) | [(984.6%)](/filings/0001437749-26-009797.md) |
| Diluted EPS | $ per share | [(0.63)](/filings/0000950170-23-011035.md) | [(1.48)](/filings/0000950170-24-044855.md) | [(30.26)](/filings/0000950170-25-046200.md) | [(6.63)](/filings/0000950170-25-046200.md) | not reported |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/icu/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $899.9k | 245,200 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $182.0k | 49,593 |  | Reduced −6,049 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $121.4k | 33,091 |  | Added +4,300 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $115.2k | 31,398 |  | Added +30,605 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $50.3k | 13,692 |  | Unchanged |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $46.4k | 12,634 |  | Reduced −15,326 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $38.2k | 10,402 |  | New +10,402 |
| [PNC Financial Services Group, Inc.](/funds/713676.md) | 2026-06-30 | $18.1k | 4,943 |  | Added +3,195 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $5.0k | 1,356 |  | Reduced −39 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $3.7k | 211,381 |  | Unchanged |

## Recent filings

[All 542 filings](/companies/icu/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-05 | 16:20 ET | [8-K](/filings/0001437749-26-032035.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032035 |
| 2026-08-12 | 16:46 ET | [10-Q](/filings/0001437749-26-027353.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027353 |
| 2026-08-12 | 16:10 ET | [8-K](/filings/0001437749-26-027314.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027314 |
| 2026-07-01 | 16:06 ET | [8-K](/filings/0001437749-26-022278.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-022278 |
| 2026-06-23 | 16:14 ET | [8-K/A](/filings/0001437749-26-021441.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-021441 |
| 2026-06-17 | 16:07 ET | [8-K](/filings/0001437749-26-020967.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-020967 |
| 2026-05-13 | 16:45 ET | [10-Q](/filings/0001437749-26-016764.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016764 |
| 2026-05-13 | 16:12 ET | [8-K](/filings/0001437749-26-016726.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-016726 |
| 2026-05-07 | 08:38 ET | [S-1/A](/filings/0001213900-26-053076.md) | Registration statement, amended | 0001213900-26-053076 |
| 2026-04-29 | 16:10 ET | [DEF 14A](/filings/0001437749-26-013871.md) | Proxy statement, period 2026-06-17 | 0001437749-26-013871 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-009797.md), filed Mar 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/58e38876-d5fe-403c-8e99-0e9d7ebed52c)

## About the filer

- CIK: 1831868
- Tickers: ICU, ICUCW
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:17 ET. No prices; not investment advice.